Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.57 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255554 | 0.84 | NPC1 (0.48) | CYP4F2CYP4A11NPC1POLBRAB9A | |
| SCHEMBL3071677 | 0.83 | CYP4F2 (0.54) | CYP4F2CYP4A11PTGDR2NPC1POLB | |
| SCHEMBL16957688 | 0.82 | CYP4F2 (0.60) | CYP4F2CYP4A11POLBHTT | |
| SCHEMBL31163873 | 0.82 | CYP4F2 (0.60) | CYP4F2CYP4A11POLBHTT | |
| SCHEMBL695880 | 0.82 | CYP4F2 (0.64) | CYP4F2CYP4A11NPC1POLBRAB9A | |
| SCHEMBL30484271 | 0.82 | CYP4F2 (0.64) | CYP4F2CYP4A11NPC1POLBRAB9A | |
| SCHEMBL6301878 | 0.81 | POLB (0.56) | NPC1POLBRAB9AFYNHTT | |
| SCHEMBL334082 | 0.81 | SLC22A12 (0.40) | CYP4F2CYP4A11NPC1POLBRAB9A | |
| SCHEMBL23673569 | 0.79 | SLC6A4 (0.42) | CYP4F2CYP4A11NPC1POLBRAB9A | |
| SCHEMBL3907087 | 0.79 | NPC1 (0.44) | CYP4F2CYP4A11NPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732456-B2 | Pyridone derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-20070208046-A1 | Pyridone derivative | MSD K.K. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1741703-A1 | PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-05-11 | — | — | US | disclosed |
| EP-1535915-A1 | FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208046-A1 | Pyridone derivative | CHRM1, XDH, MTR | CYP4F2 280/4885CYP4A11 801/4885PTGDR2 670/4885 |
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TXN2, CYP11B2, CYP11B1 | CYP4F2 34/4885CYP4A11 33/4885PTGDR2 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.